MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock,...
$306,307K
Maturities of investments
$400,000K
Proceeds from the
issuance of common stock...
$1,510K
Proceeds from the
issuance of common stock...
$15K
Net cash provided by
financing activities
$300,773K
Net cash provided by
(used in) investing...
$47,496K
Effect of foreign
exchange rate changes
$1,144K
Canceled cashflow
$7,059K
Canceled cashflow
$352,504K
Net increase
(decrease) in cash, cash...
$47,005K
Canceled cashflow
$302,408K
Tax payments
related to shares...
$7,059K
Stock-based compensation
expense
$61,575K
Accrued expenses and
other liabilities
$28,637K
Amortization of intangible
assets
$23,077K
Excess and
obsolescence reserve
$13,404K
Depreciation and
amortization of property and...
$12,862K
Amortization of right of use
asset
$11,385K
Loss on asset
disposals
-$44K
Purchase of investments
$318,668K
Purchase of property and
equipment
$33,836K
Net cash used in
operating activities
-$302,408K
Canceled cashflow
$150,984K
Net sales
$263,502K
Net loss
-$390,978K
Canceled cashflow
$263,502K
Inventory
$14,211K
Trade accounts
receivable
$13,108K
Operating lease
liabilities
-$10,900K
Prepaid expenses, other
assets and long-term...
$8,023K
Accretion of discounts and
premiums on investments
$7,202K
Accounts payable
-$6,661K
Deferred tax (benefit)
expense
-$2,071K
Unrealized foreign
exchange loss
$238K
Total expenses
$481,296K
Total cost of sales
$173,184K
Research and development
$273,311K
General and
administrative
$73,537K
Sales and marketing
$51,455K
Other segment items
$41,911K
Depreciation and
amortization
$35,939K
Restructuring charges
$5,143K
Cost of goods sold
(excluding depreciation...
$155,809K
Royalties
$10,089K
Stock-based compensation
$7,286K
Back
Back
Cash Flow
source: myfinsight.com
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)